Table 2.
Studies included in the NMA | Treatment | ITT (n) | Male (%) | Age (SD) in years | Current smokers (%) | Severe or very severe (%) | ICS usage (%) | COPD duration mean (SD) in years | Pack-years (SD) | FEV1% predicted (SD) |
---|---|---|---|---|---|---|---|---|---|---|
Decramer et al9 (DB2113360) | Tiotropium 18 μg OD | 208 | 67 | 62.6 (9.39) | 48 | 53 | 45 | NR | 41.9 (24.44) | 47.8 (13.36) |
Vilanterol 22 μg/umeclidinium 55 μg OD | 212 | 70 | 63 (8.67) | 46 | 50 | 44 | NR | 44.8 (27.65) | 48.0 (12.94) | |
Decramer et al9 (DB2113374) | Tiotropium 18 μg OD | 215 | 71 | 65.2 (8.3) | 47 | 52 | 53 | NR | 54.0 (31.59) | 47.4 (13.10) |
Vilanterol 22 μg/umeclidinium 55 μg OD | 217 | 65 | 65 (8.62) | 42 | 51 | 47 | NR | 47.8 (26.13) | 47.7 (13.55) | |
Donohue et al6 (DB2113373) | Placebo | 280 | 70 | 62.2 (9.04) | 54 | 58 | 49 | NR | 47.2 (27.21) | 46.7 (12.71) |
Vilanterol 22 μg/umeclidinium 55 μg OD | 413 | 74 | 63.1 (8.71) | 49 | 51 | 51 | NR | 46.5 (25.80) | 47.8 (13.19) | |
Maleki-Yazdi et al28 (ZEP117115) | Tiotropium 18 μg OD | 451 | 67 | 62.7 (8.50) | 54 | 58 | 53 | NR | 44.4 (25.03) | 46.5 (12.76) |
Vilanterol 22 μg/umeclidinium 55 μg OD | 454 | 68 | 61.9 (8.41) | 59 | 60 | 54 | NR | 44.1 (24.44) | 46.2 (13.02) | |
INTRUST 1 (Mahler et al17) | Tiotropium 18 μg OD | 564 | 67 | 63.4 (9.22) | 36 | 53 | 52 | 6.6 (6.45) | 47.2 (26.58) | 48.9 (11.46) |
Indacaterol 150 μg OD + tiotropium 18 μg OD | 570 | 70 | 64.0 (9.07) | 40 | 53 | 52 | 7.1 (6.12) | 47.2 (25.86) | 48.3 (9.70) | |
INTRUST 2 (Mahler et al17) | Tiotropium 18 μg OD | 570 | 68 | 62.8 (8.98) | 43 | 54 | 51 | 7.1 (6.26) | 46.3 (24.64) | 48.6 (9.76) |
Indacaterol 150 μg OD + tiotropium 18 μg OD | 572 | 63 | 63.1 (8.83) | 38 | 54 | 57 | 7.3 (6.48) | 46.2 (25.52) | 48.6 (9.74) | |
Aaron et al20 | Tiotropium 18 μg OD | 156 | 53.8 | 68.1 (8.9) | 27 | NR | 25 | 11.3 (8.8)a | 51.8 (28.0) | 42.1 (13.5) |
Tiotropium 18 μg OD + salmeterol 25 μg 2 puffs bid |
148 | 57.4 | 67.6 (8.2) | 24.3 | NR | 34.9 | NR | 48.7 (27.1) | 41.2 (13.0) | |
ENLIGHTEN (Dahl et al13) | Placebo | 113b | 76.1 | 62.9 (8.14) | 45 | 19 | 39 | 5.46 (5.1) | 38.1 (15.93) | 59.43 (12.5) |
QVA149 (indacaterol 110 μg/glycopyrronium 50 μg) OD | 226b | 77.3 | 62.5 (8.81) | 45 | 31 | 46 | 5.82 (5.74) | 36.3 (16.01) | 56.39 (13.27) | |
SPARK (Wedzicha et al16) | Tiotropium 18 μg OD | 742b | 75 | 63.6 (7.8) | 37 | 100 | 76 | 7.2 (5.5) | 47 (28) | 37.4 (8.1) |
QVA149 (indacaterol 110 μg/glycopyrronium 50 μg) OD | 741b | 76 | 63.1 (8.1) | 38 | 100 | 75 | 7.2 (5.8) | 45 (23) | 37.0 (8.1) | |
SHINE (Bateman et al11) | Placebo | 234b | 72.8 | 64.4 (8.6) | 40 | 32 | 58 | 6.4 (5.7) | NR | 55.2 (12.7) |
Tiotropium 18 μg OD | 483b | 75.0 | 63.5 (8.7) | 39 | 38 | 59 | 6.1 (5.5) | NR | 55.1 (13.5) | |
QVA149 (indacaterol 110 μg/glycopyrronium 50 μg) OD | 475b | 76.4 | 64.0 (8.9) | 40 | 34 | 56 | 6.0 (5.5) | NR | 55.7 (13.2) | |
Vogelmeier et al19 | Tiotropium 18 μg OD | 221 | 79.2 | 63.4 (9.5) | NR | NR | NR | 6.9 (6.3) | 38.6 (19.3) | 51.6 (11.2) |
Formoterol 10 μg bid + tiotropium 18 μg OD | 207 | 79.2 | 62.6 (8.8) | NR | NR | NR | 7.2 (7.0) | 37.9 (18.2) | 50.4 (10.5) | |
Placebo | 209 | 77.5 | 62.5 (8.6) | NR | NR | NR | 6.7 (6.1) | 40.1 (22.8) | 51.1 (11) | |
Tashkin et al18 | Tiotropium 18 μg OD + formoterol 12 μg bid | 124 | 65 | 63.8 (8.7) | 49 | NR | 27 | NR | NR | NR |
Tiotropium 18 μg OD + placebo bid | 131 | 68 | 63.9 (8.5) | 46 | NR | 27 | NR | NR | NR | |
Chan et al36 BI trial: 205.259 |
Tiotropium 18 μg OD | 608 | 59 | 67.0 (8.7) | 32 | NR | 66 | 9.9 (8.1) | 50.2 (22.6) | 39 (13) |
Placebo | 305 | 61 | 67.0 (9.1) | 30 | NR | 71 | 9.9 (7.9) | 51.0 (26.3) | 39 (14) | |
TIPHON (Tonnel et al37) | Tiotropium 18 μg OD | 266 | 87 | 65.0 (9.7) | 24 | 57 | 38 | 7.9 (7.6) | 44.4 (21.3) | 47 (13) |
Placebo | 288 | 85 | 64.0 (10.1) | 30 | 62 | 36 | 8.0 (7.9) | 43.0 (22.5) | 46 (12) | |
UPLIFT (Tashkin et al38 and Celli et al39) | Tiotropium 18 μg OD | 2,987 | 75 | 65.0 (8.4) | 29 | 52 | 62 | 9.9 (7.6) | 49.0 (28.0) | 40 (12) |
Placebo | 3,006 | 74 | 65.0 (8.5) | 30 | 53 | 62 | 9.7 (7.4) | 48.4 (27.9) | 39 (12) | |
Niewoehner et al40 | Tiotropium 18 μg OD | 914 | 98 | 67.6 (8.7) | 29 | NR | 61 | 12.2 (10.4) | 67.4 (35.4) | 36 (13) |
Placebo | 915 | 99 | 68.1 (8.5) | 30 | NR | 58 | 11.9 (10.5) | 69.4 (36.6) | 36 (13) | |
Brusasco et al41 | Tiotropium 18 μg OD | 402 | 77 | 63.8 (8.0) | NR | NR | NR | 9.0 (7.3) | 44.1 (22.9) | 39 (12) |
Placebo | 400 | 76 | 64.6 (8.6) | NR | NR | NR | 9.8 (7.4) | 42.4 (22.7) | 39 (12) | |
Donohue et al29 | Tiotropium 18 μg OD | 209 | 74 | 64.5 (7.9) | NR | NR | 66 | 9.2 (7.8) | 47.0 (25.0) | 41 (NR) |
Placebo | 201 | 75 | 65.6 (7.8) | NR | NR | 66 | 9.7 (7.9) | 46.0 (24.0) | 41 (NR) | |
Casaburi et al42 | Tiotropium 18 μg OD | 550 | 67 | 65.0 (9.0) | NR | NR | 44 | 8.6 (7.4) | 63.0 (31.0) | 39 (14) |
Placebo | 371 | 63 | 65.0 (9.0) | NR | NR | 40 | 8.1 (6.8) | 59.0 (30.0) | 38 (14) | |
Donohue et al43 | Tiotropium 18 μg OD | 420 | 65 | 64 (8.8) | NR | NR | 35 | NR | 50.0 (25.1) | 54 (16) |
Placebo | 425 | 61 | 63.6 (8.9) | NR | NR | 40 | NR | 49.7 (23.9) | 56 (14) | |
GLOW 2 (Kerwin et al44) | Tiotropium 18 μg OD | 267 | 63 | 63.9 (8.2) | 44 | NR | 52 | 7.5 (6.6) | 50.2 (28.0) | 56 (13) |
Placebo | 268 | 65 | 63.6 (9.1) | 46 | NR | 51 | 7.4 (6.6) | 48.0 (24.0) | 56 (14) | |
Verkindre et al45 | Tiotropium 18 μg OD | 46 | 94 | 61.0 (9.5) | 24 | NR | NR | 9.7 (6.9) | 45.6 (23.1) | 35 (9) |
Placebo | 54 | 94 | 60.0 (10.2) | 33 | NR | NR | 8.8 (6.6) | 41.8 (18.0) | 36 (9) | |
Casaburi et al46 | Tiotropium 18 μg OD | 276 | 67 | 65.0 (8.6) | NR | NR | NR | 9.3 (8.0) | 64.5 (33.1) | 39 (14) |
Placebo | 188 | 63 | 65.0 (9.0) | NR | NR | NR | 8.6 (6.9) | 60.5 (30.2) | 38 (14) | |
Covelli et al47 | Tiotropium 18 μg OD | 94 | 66 | 66.0 (8.9) | 40 | NR | 54 | 10.1 (8.1) | 66 (35.6) | 40 (13) |
Placebo | 84 | 49 | 63.0 (9.2) | 37 | NR | 58 | 10.4 (7.7) | 65 (31.2) | 39 (14) | |
Garcia et al48 | Tiotropium 18 μg OD | 123 | NR | NR | NR | NR | NR | NR | NR | NR |
Placebo | 125 | NR | NR | NR | NR | NR | NR | NR | NR | |
Moita et al49 | Tiotropium 18 μg OD | 147 | NR | NR | 28 | NR | NR | NR | NR | NR |
Placebo | 164 | NR | NR | 25 | NR | NR | NR | NR | NR |
Notes:
Duration of reported dyspnea.
Randomized population.
Abbreviations: bid, twice daily; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate; ICS, inhaled corticosteroid; ITT, intent-to-treat; NMA, network meta-analysis; NR, not reported; OD, once daily; QVA149, indacaterol/glycopyrronium; SD, standard deviation.